Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF @checkrare
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF  @checkrare
Uploaded November 2026 | Updated November 2026, 12 hours ago
A post-hoc analysis of the phase 3 TETON-2 study, presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona, found that inhaled treprostinil significantly reduced multiple disease progression events in patients with idiopathic pulmonary fibrosis (IPF).

Steven Nathan, MD, MBBCh, FCCP, Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, discusses the findings and their implications for patients.
Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPFPrimary IGF-1 DeficiencyFabry Disease: What Symptoms Should Be Better Managed By Your Medical Team?Episode 1: FDA Advisory Board’s Concerns About New Duchenne Drug, Brain Fog in Immune Thrombocyto...Diagnosing Seronegative Myasthenia GravisImportance of Patient Listening in The Development of Rare Disease TreatmentsENERGY Clinical Trial Testing Imaavy (Nipocalimab) in Warm Autoimmune Hemolytic Anemia (wAIHA)What to Expect: 2026 MGFA Scientific SessionBurdensome Symptoms in Fabry DiseasePlasma Proteomics May Predict Disease Manifestations in ALSFirst-Line Therapy Approved for Rare Lung Cancer  | The CheckRare Brief Ep 72-Year Data on Crinecerfont for the Treatment of Patients With Congenital Adrenal Hyperplasia
CheckRare |

Inhaled Treprostinil Reduces Multiple Disease Progression Events in IPF

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER